

# INCITE

## Immune Niches for Cancer Immunotherapy Enhancement

The vision of **INCITE** is to **create** a transformative **immune niche** to aid in **the generation and expansion of the fittest tumor-rejecting T cells** for more **efficient immunotherapy of cancer**


The **long-term vision** is to open up for **targeted cellular immunotherapies** against cancers and infectious diseases by learning how to **rationally manipulate adaptive immune** cell differentiation



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964955

Horizon 2020 EIC Pathfinder  
Start May 2021  
Period 4 years


# Adoptive Cell Transfer immunotherapy



CAR-T/TCR-Tg production scheme overview

- Effective against leukemias and partially against lymphomas
- Not effective against solid tumors
- T cells with stem cell features more persistent, resilient
- T stemness is currently not possible to create or maintain *in vitro*
- T stemness is physiologically occurring in secondary/tertiary immune niches


# The INCITE project outline and objectives




- Description of immune niches
- Fabrication of an artificial immune niche
- Production of more fit T cells
- Profiling of the fittest anti-tumor T cells

# Fabricating the immune niche

## The model immune niche




Ramon Roozendaal et al. *Int. Immunol.* 2008;20:1483-1487



Fletcher, A., et al. *Nat Rev Immunol* 15, 350–361 (2015).  
<https://doi.org/10.1038/nri3846>


## The components



## Readouts


- Transcriptomics (immune niches, T cells)
- T cell phenotyping and functionality
- Tumor killing efficiency *in vitro/in vivo*

## The assembly






# INCITE competences



# INCITE Exploitation and collaboration opportunities



# INCITE Team



Horizon 2020 EIC Pathfinder  
European Union Funding  
for Research & Innovation

NTNU/microsystems (coordinator)  
NTNU/modelling  
UpNano/3D printing  
TUW/material science  
MUI/bioinformatics  
OSR/lymphoid organogenesis  
OSR/translational immunotherapy  
DDI/cancer immunology  
RCI/clinical immunotherapy  
BOUKJE/dissemination

Øyvind Halaas. [oyvind.halaas@ntnu.no](mailto:oyvind.halaas@ntnu.no)  
Jan Torgersen, [jan.torgersen@ntnu.no](mailto:jan.torgersen@ntnu.no)  
Markus Lunzer [Markus.Lunzer@upnano.at](mailto:Markus.Lunzer@upnano.at)  
Aleksandr Ovsianikov [Aleksandr.Ovsianikov@tuwien.ac.at](mailto:Aleksandr.Ovsianikov@tuwien.ac.at)  
Zlatko Trajanoski [zlatko.trajanoski@i-med.ac.at](mailto:zlatko.trajanoski@i-med.ac.at)  
Andrea Brendolan [brendolan.andrea@hsr.it](mailto:brendolan.andrea@hsr.it)  
Vincenzo Russo [russo.vincenzo@hsr.it](mailto:russo.vincenzo@hsr.it)  
Pierre van der Bruggen [pierre.vanderbruggen@uclouvain.be](mailto:pierre.vanderbruggen@uclouvain.be)  
Luca Gattinoni [luca.gattinoni@ukr.de](mailto:luca.gattinoni@ukr.de)  
Boukje Ehlen [boukje@boukje.com](mailto:boukje@boukje.com)



Norway



Italy



Austria



Austria



Belgium



Germany



Netherlands



MEDICAL  
UNIVERSITY  
INNSBRUCK

Austria